Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Akriti Seth
Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.
After receiving a CGT designation by the FDA for its generic version of Amicar, Amneal gets 180 days of exclusivity.
Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.
The BGMA has condemned anti-competitive behavior in the UK after Aspen paid the NHS £8m in a landmark case over “illegal market sharing”.
Stada and Gedeon Richter have launched their respective Movymia and Terrosa teriparatide biosimilars in Europe, with Stada eyeing 24 individual countries.
Sun Pharma continues to build its global specialty business with an increasing focus on China and Japan. As it revealed first-quarter results, the company announced a licensing deal with CMS and a new leader for its operations in China.